Gamma Knife Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The Gamma Knife Market has experienced significant growth, generating global revenue of approximately US$ 199 Million in 2024. The market is poised for continued expansion projected to reach an estimated valuation of around US$ 300 Million by the end of 2031. Several factors contribute to the growth of the Gamma Knife Market.

Gamma Knife for Non-Invasive Treatment

One of the main drivers of market expansion for the Gamma Knife is the worldwide increase in obesity cases. Doctors are recommending Gamma Knife procedures to obese patients due to its non-invasive nature. Non-invasive procedures hold more than 50% of the market share for aesthetic medicine, creating significant potential for Gamma Knife procedures.

Effective Stereotactic Radiosurgery

Stereotactic radiosurgery has become an alternative to conventional craniotomy procedures for treating cancer. The Gamma Knife method is widely used because it targets tumor cells without harming healthy cells, resulting in fewer adverse effects. It offers better visualization, remote accessibility, and team communication options.

Rising Prevalence of Neurological Disorders

A significant portion of the population, especially the elderly, is affected by various neurological disorders such as multiple sclerosis, Parkinson's disease, brain tumors, epilepsy, dementia, and stroke. Gamma Knife radiosurgery delivers targeted gamma radiation beams to the tumor site, making it suitable for treating complex neurological disorders. The quick recovery time and non-invasive nature of the procedure contribute to future market growth.

How Can the Global Market Grow?

'Rising Prevalence of Brain Tumors and Combination Treatment Therapies'

Brain tumors rank eighth in the list of most common cancers and third in cancer-related deaths among individuals aged 40 and older, according to the American Cancer Society. The increasing aging population is expected to drive demand for brain tumor treatment and rehabilitation, positively impacting market growth. Gamma Knife radiosurgery is a suitable treatment for numerous brain metastases, offering high integral dosage to the tumor with minimal impact on nearby healthy brain tissue. Combining biological and immunological agents with Gamma Knife radiosurgery further enhances treatment options.

Factors Affecting Market Growth:

'High Cost and Limited Awareness'

The high cost of Gamma Knife radiotherapy machines and associated investment and maintenance expenses may deter adoption in emerging economies, potentially affecting market growth. These machines are more expensive than other radiation equipment. Additionally, a dearth of skilled specialists who can operate Gamma Knife equipment may limit market expansion.

Why is the U.S. Market Booming?

The Gamma Knife procedure's less invasive nature compared to other treatments makes it the preferred choice in the United States. Rising disposable income also contributes to increased accessibility, fueling market growth.

Will Germany Be a Lucrative Market for Gamma Knife?

Major companies in the Gamma Knife industry are investing in research and development to modify existing models with the latest technologies, further stimulating market growth.

How is Japan Emerging as a Prominent Market?

Japan is expected to witness increased market share due to a rising incidence of vascular abnormalities, which result from lifestyle factors affecting many citizens.

Competitive Landscape:

Leading market players are strengthening their positions through mergers and acquisitions. Additionally, players are forming strategic alliances with competitors in other markets to drive growth.

Key Companies Profiled:

• Elekta AB
• Varian Medical Systems
• Huiheng Medical, Inc.
• MASEP Medical Science Technology Development (Shenzhen) Co., Ltd.
• Akesis Inc.
• Cyber Medical Corporation Limited.
• Masep Infini Global, Inc.
• Nordion, Inc.
• Hokai
• ET Medical Group
• American Shared Hospital Services

Market Segmentation

Disease Indication:

• Brain Metastasis
• Cancer
• Arteriovenous Malformation (AVM)
• Trigeminal Neuralgia
• Others

Organ Treated:

• Head
• Neck
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

This product will be delivered within 1-3 business days.